Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...

Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations ATLANTA, GA - February 24 ...

GeoVax Labs' Mpox vaccine still has a long way to go before gaining approval or generating any type of revenue. Its treatment is still in pre-clinical development. That phase of development alone ...

Ethical Vaccine Development & Public Confidence – GeoVax embraces open regulatory processes, rigorous safety standards, and public access to data, ensuring confidence in its vaccines. These principles ...

Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...

Geovax Labs (NASDAQ:GOVX) just reported results for the second quarter of 2024. Geovax Labs reported earnings per share of -$1.99. This was above the analyst estimate for EPS of -$4.43.

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness. ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York und ...

ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J.

Dr. Montgomery Rice will be formally recognized at the Atlanta Business Chronicle's second annual Health Care Champion Awards ceremony on March 20, 2025.

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...